Drug Database
Back to search

Netherlands· NL-76e287cb3b98

Soliris, concentraat voor oplossing voor infusie 10 mg/ml (300 mg/30 ml)

A eculizumab product containing eculizumab, registered in Netherlands by Alexion Europe SAS. The same ATC class is registered in 13 of our 19 countries.

ATC L04AJ01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedSoliris, concentraat voor oplossing v…ATCL04AJ01REGISTER NO.NL-76e287cb3b98PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about eculizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Eculizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AJ01 (eculizumab), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search eculizumab products by name

Eculizumab · ATC L04AJ01

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ECULIZUMAB
Manufacturer
Alexion Europe SAS
Country
Netherlands (NL)
ATC code
L04AJ01
ATC class
Eculizumab
Defined daily dose
64 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/07/393

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for eculizumab.

Graded by severity as the source publishes them — 2 minor. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check eculizumab against other medicinesHow interaction checks work

Eculizumab · interactions on record

2 records

  • 2 minor

Most severe, free to view

    Mechanism and what to do, in the interaction check
    Interaction register. Grades as the source publishes them.

    Same medicine, other countries

    Eculizumab in 15 other countries

    What each register calls a product with the same active substance — salts and hydrates count as the same.

    All eculizumab products

    Authorised across Europe · EMA

    The same active substance is authorised in 3 EEA countries. Names it is sold under:

    • Iceland · Bekemv, Soliris
    • Liechtenstein · Soliris
    • Norway · Bekemv, Soliris

    Source: European Medicines Agency, Article 57 product data.

    Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

    For developers

    The same record over the API, and the raw payload
    GET /v1/drugs/2d5ad9b6-d9ae-4bca-a2d9-7670205c6af0
GET /v1/drugs/2d5ad9b6-d9ae-4bca-a2d9-7670205c6af0?format=fhir

    Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

    {
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Eculizumab",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp73547",
  "excipients": [
    "DISODIUM PHOSPHATE, HYDRATE FORM UNKNOWN (E 339) (RI)",
    "NATRIUMCHLORIDE",
    "POLYSORBAAT 80 (E 433)",
    "SODIUM DIHYDROGEN PHOSPHATE (HYDRATE FORM UNKNOWN) (E 339) (RI)",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "WATER, GEZUIVERD"
  ],
  "substances": [
    "ECULIZUMAB"
  ],
  "leaflet_url": null,
  "authorised_at": "2007/06/20",
  "procedure_number": "EMEA/H/C/000791",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/07/393",
  "additional_monitoring": "N"
}
    API referenceMCP serverPlans

    See everything about eculizumab.

    This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

    Try it freeOpen in the console